CG Oncology (NASDAQ:CGON) Director Sells $41,430.00 in Stock

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard Post sold 1,000 shares of the stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $41.43, for a total transaction of $41,430.00. The sale was disclosed in a document filed with the SEC, which is available at this link.

CG Oncology Stock Up 3.2%

NASDAQ:CGON traded up $1.30 on Tuesday, reaching $42.55. The stock had a trading volume of 1,048,093 shares, compared to its average volume of 991,050. The company has a market capitalization of $3.24 billion, a P/E ratio of -20.86 and a beta of 1.32. CG Oncology, Inc. has a 1-year low of $14.80 and a 1-year high of $45.56. The stock has a fifty day moving average price of $39.70 and a 200-day moving average price of $30.99.

CG Oncology (NASDAQ:CGON) last posted its earnings results on Friday, November 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.57). The company had revenue of $1.51 million during the quarter, compared to analysts’ expectations of $0.07 million. CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 21.55%. Sell-side analysts predict that CG Oncology, Inc. will post -1.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Winthrop Capital Management LLC bought a new stake in shares of CG Oncology during the second quarter worth approximately $38,000. Strengthening Families & Communities LLC acquired a new stake in CG Oncology during the 3rd quarter worth $40,000. CWM LLC raised its position in shares of CG Oncology by 3,957.7% during the 1st quarter. CWM LLC now owns 2,110 shares of the company’s stock valued at $52,000 after acquiring an additional 2,058 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of CG Oncology by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company’s stock valued at $77,000 after purchasing an additional 398 shares during the period. Finally, PNC Financial Services Group Inc. boosted its position in shares of CG Oncology by 15.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock worth $85,000 after purchasing an additional 433 shares during the last quarter. Institutional investors own 26.56% of the company’s stock.

Analyst Ratings Changes

CGON has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a research note on Wednesday, October 8th. Jones Trading initiated coverage on CG Oncology in a report on Monday, September 8th. They issued a “buy” rating and a $50.00 price target for the company. Royal Bank Of Canada increased their price objective on shares of CG Oncology from $53.00 to $61.00 and gave the stock an “outperform” rating in a report on Monday. Zacks Research upgraded shares of CG Oncology from a “strong sell” rating to a “hold” rating in a research report on Monday, September 1st. Finally, JPMorgan Chase & Co. increased their price target on shares of CG Oncology from $41.00 to $47.00 and gave the company an “overweight” rating in a research note on Friday, September 26th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $59.50.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.